Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's [Seeking Alpha]
Anavex Life Sciences Corp. (AVXL)
NASDAQ:AMEX Investor Relations:
anavex.com/share-data
Company Research
Source: Seeking Alpha
AVXL's Phase 2B/3 trial failed to achieve statistical significance on both primary endpoints, undermining regulatory pathways in both Europe and the U.S. Despite a $120 million cash balance and a broad pipeline, AVXL's recent clinical outcomes in Alzheimer's, Rett syndrome, and schizophrenia remain unconvincing. I remain bearish on AVXL, citing weak fundamentals, high short interest, and a lack of clear near-term catalysts. Jacob Wackerhausen/iStock via Getty Images Thesis I have covered Anavex Life Sciences ( AVXL ) in November 2025, after my initial coverage a year ago, ahead of the opinion of the European Committee for Medicinal Products for Human Use [CHMP] on This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for
Show less
Read more
Impact Snapshot
Event Time:
AVXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVXL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVXL alerts
High impacting Anavex Life Sciences Corp. news events
Weekly update
A roundup of the hottest topics
AVXL
News
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 [Yahoo! Finance]Yahoo! Finance
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026GlobeNewswire
- Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]Yahoo! Finance
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s DiseaseGlobeNewswire
- INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the FirmPR Newswire
AVXL
Earnings
- 11/25/25 - Beat
AVXL
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 11/25/25 - Form 10-K
- AVXL's page on the SEC website